Non-Alcoholic Fatty Liver Disease (NAFLD)

Terminology Update: In 2023, a multinational consensus renamed NAFLD to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and NASH to Metabolic Dysfunction-Associated Steatohepatitis (MASH). Both old and new terminology may appear in clinical material. This guide uses both interchangeably.

01Pathophysiology

NAFLD is fundamentally a disease of insulin resistance and disordered lipid metabolism. The pathophysiology is classically explained through the "multiple-hit" model, which has replaced the older "two-hit" hypothesis.

The first hit is hepatic steatosis itself. In the setting of insulin resistance, adipose tissue undergoes excessive lipolysis, releasing a surplus of free fatty acids (FFAs) into the portal circulation. The liver takes up these FFAs and, combined with increased de novo lipogenesis (driven by hyperinsulinemia activating sterol regulatory element-binding protein 1c, or SREBP-1c), fat accumulates within hepatocytes. At the same time, the export of triglycerides via very-low-density lipoprotein (VLDL) is impaired, worsening the imbalance. This results in macrovesicular steatosis, which defines simple NAFL.

The subsequent hits transform benign steatosis into NASH. Accumulated lipids generate reactive oxygen species (ROS) through mitochondrial beta-oxidation overload and endoplasmic reticulum stress. This oxidative stress injures hepatocyte membranes and triggers an inflammatory cascade. Additionally, gut-derived endotoxins (lipopolysaccharides) activate hepatic Kupffer cells via Toll-like receptor 4 (TLR4), amplifying the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. Adipokine imbalance (decreased adiponectin, increased leptin) further promotes inflammation and fibrogenesis.

Once chronic inflammation is established, hepatic stellate cells become activated and begin depositing extracellular matrix (collagen), leading to progressive fibrosis. Over years to decades, this can advance through stages of fibrosis to cirrhosis and eventually hepatocellular carcinoma (HCC). The progression pathway is:

Simple Steatosis (NAFL) → NASH → Fibrosis → Cirrhosis → HCC

A critical teaching point: HCC can occasionally arise from NASH even before cirrhosis is established, though this is less common. Also, the leading cause of death in NAFLD patients is not liver-related disease but rather cardiovascular disease, which directly reflects the shared pathophysiology of insulin resistance and metabolic syndrome.

02Classification and Clinical Manifestation

Clinical Features by Stage:

A key exam concept: the AST/ALT ratio inverts as fibrosis advances. In early NAFLD, ALT > AST (ratio < 1). When cirrhosis develops, AST rises above ALT (ratio > 1). This is because sinusoidal fibrosis impairs clearance of AST from the bloodstream, and cirrhotic hepatocytes have diminished ALT production. This pattern shift is a commonly tested discriminator.

03Diagnostic Workup

The workup begins with identifying the right clinical context. The classic vignette describes an overweight or obese patient with metabolic syndrome who has incidentally discovered mildly elevated transaminases during routine bloodwork, or whose imaging study (often ordered for another reason) reveals a fatty liver.

Step 1: Establish steatosis and rule out competing etiologies. Order a comprehensive metabolic panel and liver function tests. The hallmark pattern is ALT elevated more than AST, with the AST/ALT ratio less than 1. Next, you must systematically exclude other causes of chronic liver disease: hepatitis B surface antigen and hepatitis C antibody, iron studies and transferrin saturation (hemochromatosis), ceruloplasmin in younger patients (Wilson disease), antinuclear antibody and anti-smooth muscle antibody (autoimmune hepatitis), and alpha-1 antitrypsin level. A careful alcohol history is essential. NAFLD requires alcohol consumption below the threshold (< 30 g/day for men, < 20 g/day for women, roughly equivalent to about 2 standard drinks and 1.5 standard drinks respectively).

Step 2: Confirm hepatic steatosis with imaging. The best initial imaging test is abdominal ultrasound. It is inexpensive, widely available, and has reasonable sensitivity for detecting moderate-to-severe steatosis. The classic finding is a diffusely bright (hyperechoic) liver parenchyma relative to the adjacent right kidney cortex. However, ultrasound cannot reliably distinguish simple steatosis from NASH, nor can it accurately stage fibrosis.

Step 3: Risk-stratify for fibrosis. This is where exam questions often focus. Not every patient with fatty liver needs a biopsy. Use validated noninvasive scoring systems first:

• FIB-4 Index = $\frac{\text{Age}\times \text{AST}}{\text{Platelet count}\times \sqrt{\text{ALT}}}\backslash frac\{\backslash text\{Age\}\; \backslash times\; \backslash text\{AST\}\}\{\backslash text\{Platelet\; count\}\; \backslash times\; \backslash sqrt\{\backslash text\{ALT\}\}\}$

A FIB-4 score < 1.30 has a high negative predictive value for advanced fibrosis (the patient can be monitored conservatively). A score > 2.67 is concerning for advanced fibrosis and warrants further evaluation. Scores in between are indeterminate and typically prompt transient elastography.

Transient elastography (FibroScan) measures liver stiffness as a surrogate for fibrosis. It is increasingly used as the intermediate step between noninvasive scores and biopsy.

Step 4: Liver biopsy. This remains the gold standard for confirming NASH, grading necroinflammatory activity using the NAFLD Activity Score (NAS), and staging fibrosis from F0 (none) to F4 (cirrhosis). Biopsy is indicated when: there is clinical suspicion for NASH with intermediate or high fibrosis risk, when competing diagnoses cannot be resolved noninvasively, or when a treatment decision (such as starting pharmacotherapy) depends on histological confirmation.

04Management & Treatment

Lifestyle modification is the single most important and universally recommended intervention. A sustained weight loss of at least 7% of body weight improves steatosis and inflammation, while 10% or more can lead to regression of fibrosis. This is achieved through a combination of caloric restriction (a Mediterranean-style diet rich in monounsaturated fats, vegetables, and whole grains, and low in refined carbohydrates and fructose) and regular moderate-intensity aerobic exercise (at least 150 minutes per week). Even exercise without weight loss improves hepatic steatosis independently.

Vitamin E at 800 IU/day is recommended for adult, non-diabetic patients with biopsy-proven NASH. The PIVENS trial demonstrated improvement in steatosis and inflammation, though not fibrosis. It is not recommended in patients with diabetes (as data is less convincing in this population), patients without biopsy confirmation, or those with cirrhosis. Long-term safety concerns include a possible slight increase in all-cause mortality and prostate cancer risk at high doses, though these associations remain debated.

Pioglitazone (30-45 mg/day), a thiazolidinedione insulin sensitizer, improves histological features of NASH including fibrosis in some studies. It can be used in both diabetic and non-diabetic patients with NASH. Key side effects that are commonly tested include weight gain, fluid retention (contraindicated in heart failure, NYHA class III-IV), increased fracture risk (especially in postmenopausal women), and a potential association with bladder cancer.

GLP-1 receptor agonists (particularly semaglutide) have shown resolution of NASH on biopsy and are preferred when the patient has coexisting T2DM or obesity, as they address multiple metabolic targets simultaneously.

Resmetirom is a selective thyroid hormone receptor beta agonist that was the first drug to receive FDA approval with a labeled indication for noncirrhotic NASH with moderate-to-advanced fibrosis (stages F2-F3). It works by enhancing hepatic lipid metabolism and reducing hepatic fat, inflammation, and fibrosis. This is a newer but increasingly tested concept.

Statins are safe in NAFLD and NASH, including compensated cirrhosis. This is one of the most commonly tested management pearls. Students frequently and incorrectly avoid statins in patients with "liver disease," but current guidelines strongly recommend statins for cardiovascular risk reduction in NAFLD patients. Statins are only contraindicated in decompensated cirrhosis (Child-Pugh B or C). Given that cardiovascular disease is the leading cause of death in NAFLD, undertreating dyslipidemia is a clinical error.

Avoid hepatotoxic agents, minimize unnecessary medications, and strongly advise against alcohol consumption, even at "social" levels, as it accelerates disease progression.

For patients who progress to cirrhosis, standard cirrhosis care applies: surveillance for HCC with ultrasound and alpha-fetoprotein (AFP) every 6 months, screening for esophageal varices with upper endoscopy, and liver transplant evaluation when appropriate.

05Differential Diagnosis & Distractors

06Traps & High-Yield Pearls

The most common way students lose points on NAFLD questions falls into a few predictable patterns.

Trap #1: Withholding statins because of "liver disease." Vignettes will describe a patient with NAFLD, elevated ALT, and dyslipidemia, then ask for the next best step in managing their cardiovascular risk. The wrong instinct is to avoid statins due to elevated transaminases. The correct answer is to prescribe them. Statins are safe and indicated in NAFLD with compensated liver disease. Only decompensated cirrhosis (Child-Pugh B/C) is a true contraindication.

Trap #2: Confusing the AST/ALT ratio between NAFLD and ALD. Students must internalize that in NAFLD, ALT > AST (ratio < 1), while in alcoholic hepatitis, AST > ALT with a ratio often > 2:1. A vignette that gives you an AST/ALT ratio greater than 2 in an obese patient should immediately make you question whether alcohol use is the real driver.

Trap #3: Ordering a biopsy on everyone. Not every patient with fatty liver needs a biopsy. The tested management logic involves stepwise risk stratification: noninvasive scores (FIB-4) first, then elastography if indeterminate, and biopsy reserved for cases where the clinical question cannot be answered otherwise or when it will change management.

Trap #4: Forgetting that cardiovascular disease is the number one killer. A vignette may describe a patient dying from a myocardial infarction and ask about the leading cause of mortality in NAFLD. The answer is cardiovascular disease, not liver failure or HCC. This underscores why aggressively managing metabolic risk factors (hypertension, diabetes, dyslipidemia) is paramount.

Trap #5: Giving vitamin E to the wrong patient. Vitamin E is only for non-diabetic, biopsy-proven NASH without cirrhosis. A question that adds diabetes to the vignette or omits biopsy confirmation is testing whether you know these restrictions.

The core competency being tested across NAFLD questions is your ability to recognize an asymptomatic metabolic patient with incidentally elevated transaminases, correctly exclude competing etiologies through a systematic workup, risk-stratify for fibrosis using noninvasive tools before reaching for biopsy, and manage the whole patient (cardiovascular risk included) rather than focusing narrowly on the liver.